President & CEO
Mr. Manusos also holds the role of Chief Operating Officer of FUJIFILM Cellular Dynamics Inc. (FCDI) overseeing the life sciences and cell therapy divisions. Since joining the organization in 2018, he developed a strategic vision for the cell therapies division and forged many new relationships with key industry leading companies on behalf of FCDI. Prior to joining FCDI, Mr. Manusos held senior executive positions at Baxter Healthcare, Takeda Pharmaceuticals Company and Abbott Laboratories where is played key roles in successful M&A, strategic transactions, integration and general management. Mr. Manusos received his MBA from Northwestern University, J.L. Kellogg Graduate School of Management and his BBA, Operations Management from University of Wisconsin-Whitewater.
David Gamm, MD PhD
Co-Founder & Chief Scientific Officer
Dr. Gamm is a practicing pediatric ophthalmologist at the University of Wisconsin, and a leader in the field of retinal cell differentiation from human pluripotent stem cells. At the University of Wisconsin-Madison, he holds positions as RRF Emmett A. Humble Distinguished Director of the McPherson Eye Research Institute, Associate Professor of Ophthalmology and Visual Sciences, Sandra Lemke Trout Chair in Eye Research, and Principal Investigator in the Waisman Center Stem Cell Research Program and the UW Stem Cell and Regenerative Medicine Center. Three-dimensional optic vesicle-based differentiation of human pluripotent stem cells into retinal cells, including photoreceptors, was first described in Dr. Gamm's laboratory.
Lucas Chase, PhD
Director, Research & Development
Dr. Chase is Director, Ocular Cell Therapy, at FCDI where he has led the development of induced pluripotent stem cell (iPSC)-based ocular therapeutics since 2014. Prior to that, he was Group Leader in Cell Biology R&D at CDI where he led efforts to develop a series of iPSC-derived neural cell models. Before joining CDI, Dr. Chase worked at Life Technologies (acquired by Thermo Fisher Scientific) where he focused on the development of cGMP stem cell culture medium, advanced cellular models and drug discovery assays. Dr. Chase obtained his Ph.D. in 2006 from the University of Minnesota - Twin Cities in the Molecular, Cellular, Developmental Biology and Genetics Program in the Lab of Dr. Catherine Verfaillie.
Joe Phillips, PhD
Director, Preclinical Studies
Dr. Phillips has served as Director of Preclinical Studies since the inception of Opsis Therapeutics. He possesses 20 years of vision research experience, including preclinical testing for subretinal prosthetics (Optobionics, Atlanta VA hospital), visual psycophysics (University of Georgia), neuroprotective strategies (Emory University), endogenous repair mechanisms (University of Houston), and retinal stem cell and regenerative medicine (University of Wisconsin). Dr. Phillips holds a PhD in Vision Science, and brings pertinent knowledge of retinal cell biology, animal models, and visual function testing to the company.
Amanda Mack, PhD
Director, iPSC Technologies
Dr. Mack is Director, iPSC Reprogramming at FCDI where she has led the development of induced pluripotent stem cell (iPSC) technology since 2007. The iPSC platform is a core competency at CDI, and in 2013 it was was successfully implemented at CDI's facility in Novato, CA, where the world's largest bank of iPSC lines is being generated on behalf of a California Institute of Regenerative Medicine (CIRM)-funded project. Currently, she leads ongoing efforts to develop GMP-compliant protocols for therapeutic grade iPSCs , both autologous and haplotype-matched, which serve as the starting point for the development and manufacturing of a range of cell therapy products. Dr. Mack obtained her Ph.D. in Cancer Biology from the McArdle Laboratory for Cancer Research at the University of Wisconsin Madison under the mentorship of Dr. Bill Sugden in 2007.
Carter is an entrepreneur focused on the areas of regenerative medicine and precision medicine. He is a founder of Opsis Therapeutics, RPRD Diagnostics, Dianomi Therapeutics, and Vascugen where he currently serves at CEO. Previously he held various positions at leading biotechnology companies including FCDI, Meso Scale Diagnostics, Life Technologies, and Ingenuity Systems.